Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence

References

• Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62(6), 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• The World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. World Health Organization, Geneva, Switzerland (2001).
   Google Scholar
• US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. Depression Guideline Panel: clinical practice guidelines, Number 5. Depression in Primary Care: Volume 1. Detection and diagnosis. US Department of Health and Human Services, Rockville, MD, USA, AHCPR Publication Number 93-0550 (1993).
   Google Scholar
• Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr. Clin. North Am.9, 85–102 (1996).
   Google Scholar
• Kessler RC, Berglund C, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289(23), 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition; Text Revision). American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Evans DL, Charney DS, Lewis L et al. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry58(3), 175–189 (2005).
   PubMed Web of Science ®Google Scholar
• Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol. Psychiatry54, 216–226 (2003).
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry64(12), 1465–1475 (2003).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (2nd Edition). Cambridge University Press, Cambridge, UK (2000).
   Google Scholar
• Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am.26(2), 457–494 (2003).
   PubMed Web of Science ®Google Scholar
• Rush A. STAR*D: what have we learned? Am. J. Psychiatry164(2), 201–204 (2007).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, O’Donovan C. The human cost of not achieving full remission in depression. Can. J. Psychiatry49(3 Suppl. 1), S10–S16 (2004).
   Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology31(9), 1841–1853 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163, 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Why do we need new and better antidepressants? Int. Clin. Psychopharmacol.21(Suppl. 1), S1–S10 (2006).
   Web of Science ®Google Scholar
• Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol. Psychiatry.44(5), 348–360 (1998).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Grady MM, Moret C et al. SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectr.10(9), 732–747 (2005).
   PubMed Web of Science ®Google Scholar
• Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J. Clin. Psychiatry64(Suppl. 13), 26–29 (2003).
   PubMed Web of Science ®Google Scholar
• Guldiken S, Guldiken B, Arikan E et al. Complete relief of pain in acute painful diabetic neuropathy of rapid glycemic control (insulin neuritis) with venalafaxine HCL. Diabetes Nutr. Metab.17, 247–249 (2004).
   PubMedGoogle Scholar
• Arnold LM, Lu Y, Crofford LJ et al. A double-blind multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum.50, 2974–2984 (2004).
   PubMed Web of Science ®Google Scholar
• Mom CH, Buijs C, Willemse PH et al. Hot flashes in breast cancer patients. Crit. Rev. Oncol. Hematol.57(1), 63–77 (2006).
   PubMed Web of Science ®Google Scholar
• Barton D, La VB, Loprinzi C et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol. Nurs. Forum29(1), 33–40 (2002).
   PubMedGoogle Scholar
• Deecher DC, Beyer CE, Johnston G et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther.318(2), 657–665 (2006).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology25(6), 871–880 (2001).
   PubMed Web of Science ®Google Scholar
• Andree TH, Rosenzweig-Lipson S, Lin Q et al. Preclinical evidence for antidepressant and anxiolytic efficacy for the new dual serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate (DVS). Presented at: Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum. Chicago, IL, USA, 9–13 July 2006.
   Google Scholar
• Parker V, Richards LS, Nichols AI et al. The absolute bioavailability of sustained-release formulation of desvenlafaxine succinate extended release in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA 2–5 March 2005.
   Google Scholar
• Parks V, Patat A, Behrle J et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA 2–5 March 2005.
   Google Scholar
• Shilling AD, Yung-Sciame R, Leung L. Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, duloxetine, paroxetine, sertraline, and bupropion in human cytochrome P450 activities. Presented at: International Society for the Study of Xenobiotics Meeting. Maui, Hawaii, USA 23–27 October 2005.
   Google Scholar
• Preskorn SH, Borges-Gonzalez S, Flockhart D. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part II. J. Psychiatr. Pract.12(5), 312–316 (2006).
   PubMedGoogle Scholar
• Baird-Bellaire S, Patat A, Faunoux N et al. Effects of chronic hepatic impairment on the pharmacokinetics and safety of desvenlafaxine succinate extended release. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Baltimore, MD, USA 8–11 March 2006.
   Google Scholar
• Kamath J, DeMartinis N, Handratta V. Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. Future Neurol.2(4), 361–371 (2007).
   Google Scholar
• Kornstein SG, Thase ME, Tummala R et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. Presented at: American Psychiatric Association Annual Meeting. Washington, DC, USA 3–8 May 2008.
   Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R. Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J. Clin. Psychiatry68(5), 677–688 (2007).
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int. Clin. Psychopharmacol.22, 338–347 (2007).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr. Med. Res. Opin.24(7), 1877–1890 (2008).
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U et al. Efficacy, safety and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int. Clin. Psychopharmacol.23(5), 243–253 (2008).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J. Clin. Psychiatry68(11), 1663–1672 (2007).
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int. Clin. Psychopharmacol.23(4), 188–197 (2008).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. Safety and tolerability of desvenlafaxine versus placebo in the treatment of major depressive disorder: a pooled analysis. Presented at: 48th Annual NCDEU Meeting. Phoenix, AZ, USA 27–30 May 2008.
   Google Scholar
• Thase ME, Guico-Pabia C, Tourian KA. Blood pressure changes associated with desvenlafaxine 50, 100, 200 and 400 mg/day: pooled results from five placebo-controlled, fixed dose studies in depressed outpatients. Presented at: 48th Annual NCDEU Meeting. Phoenix, AZ, USA 27–30 May 2008.
   Google Scholar
• Montgomery SA, Fava M, Padmanabhan SK, Tourian KA, Guico-Pabia C. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine 50, 100, 200 and 400 mg/day for treatment of major depressive disorder. Presented at: 48th Annual NCDEU Meeting. Phoenix, AZ, USA 27–30 May 2008.
   Google Scholar
• Koch S, Hemrick-Luecke SK, Thompson LK et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology45(7), 935–944 (2003).
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S; Study 315 investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet. Gynecol.111(1), 77–87 (2008).
   PubMed Web of Science ®Google Scholar